Table 5

External responsiveness of disease activity measures in patients with primary Sjögren's syndrome treated with rituximab

ESSPRI
OutcomeBaselineΔ0–16Δ0–24Δ0–36Δ0–48Δ0–60
ESSDAIρ−0.0560.011−0.0100.1170.0880.139
ρ0.7770.9540.9620.5690.6820.356
Patient's GDAρ0.6200.4310.3150.5250.3930.623
ρ0.0000.0220.1100.0060.0580.001
Physician's GDAρ0.3490.0880.2550.1160.0620.103
ρ0.0690.6570.2000.5740.7720.625
IgM-Rfρ0.0900.1170.1870.3060.3790.324
ρ0.6500.5520.3490.1280.0580.115
SWSρ−0.036−0.0050.128−0.174−0.288−0.285
ρ0.8550.9810.5240.3950.1720.199
ESSDAI
OutcomeBaselineΔ0–16Δ0–24Δ0–36Δ0–48Δ0–60
Patient's GDAρ0.1450.3490.3500.1210.3950.509
ρ0.4630.0680.0680.5390.0370.007
Physician's GDAρ0.3780.3890.4350.5000.7430.736
ρ0.0470.0410.0210.0070.0000.000
IgM-Rfρ−0.082−0.122−0.2250.094−0.141−0.125
ρ0.6770.5360.2500.6350.4760.533
SWSρ−0.137−0.2030.0290.175−0.029−0.066
ρ0.4860.3090.8820.3720.8820.758
  • Δ0–16, change from baseline to 16 weeks; Δ0–24, change from baseline to 24 weeks; Δ0–36, change from baseline to 36 weeks; Δ0–48, change from baseline to 48 weeks; Δ0–60, change from baseline to 60 weeks.

  • ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patients Reported Index; GDA, global disease activity assessment; IgM-Rf, rheumatoid factor; SWS, stimulated whole salivary flow.